Pyrazole compound and medicinal composition containing the same

Details Pyrazole compound and medicinal composition containing the same Pyrazole compound and medicinal composition containing the same

2003-05-29

2008-09-30

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S361500

Reexamination Certificate

active

07429609

ABSTRACT:
The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.Wherein R1designates —(CO)h—(NRa)j—(CRb═CRc)k—Ar (wherein Ra, Rband Rceach independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6alkyl group or the like;Cy designates a 5- or 6-membered heteroaryl; andV each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).

REFERENCES:
patent: 3705175 (1972-12-01), Gorog et al.
patent: 3755332 (1973-08-01), Wasley et al.
patent: 6897231 (2005-05-01), Bhagwat et al.
patent: 2002/0103229 (2002-08-01), Bhagwat et al.
patent: 2004/0009968 (2004-01-01), Binch et al.
patent: 1168437 (1964-04-01), None
patent: 1266763 (1968-04-01), None
patent: 239191 (1987-09-01), None
patent: 594001 (1994-04-01), None
patent: 1 110 957 (2001-06-01), None
patent: 50157363 (1975-12-01), None
patent: 1-190681 (1989-07-01), None
patent: 1147712 (1985-03-01), None
patent: WO-98/52948 (1998-11-01), None
patent: WO-99/07705 (1999-02-01), None
patent: WO-99/20624 (1999-04-01), None
patent: WO-00/35906 (2000-06-01), None
patent: WO-00/35909 (2000-06-01), None
patent: WO-00/35921 (2000-06-01), None
patent: WO-00/56710 (2000-09-01), None
patent: WO-00/64872 (2000-11-01), None
patent: WO-00/75118 (2000-12-01), None
patent: WO-01/12609 (2001-02-01), None
patent: WO-01/12621 (2001-02-01), None
patent: WO-01/23378 (2001-04-01), None
patent: WO-01/23379 (2001-04-01), None
patent: WO-01/23382 (2001-04-01), None
patent: WO 0153268 (2001-07-01), None
patent: WO-01/91749 (2001-12-01), None
patent: WO-02/10137 (2002-02-01), None
patent: WO 02010137 (2002-02-01), None
patent: WO-02/083648 (2002-10-01), None
patent: WO 03064397 (2003-08-01), None
Ortoleva, G. Gazzetta Chimica Italiana (1908), 37(2), 71-82.
Patridge et al. Abstract from Journal of the Chemical Society 1964, 3663-9.
Burmistrov et al. Abstract from Khimiya Geterosiklicheskikh Soedinenii 1973, 2, 249-51.
Simon et al. Justus Liebigs Annalen der Chemie 1966, 697, 17-41. (the CAS abstract and structures is provided).
O'Neill, L. A.J. Nature Reviews Drug Discovery 2006, 1-15.
Piozzi et al. Gazzetta Chimica Italiana 1965, 95(7), 814-24.
Burmistrov et al. Khimiya Geterotsiklicheskikh Soedinenii 1973, 2, 249-51.
Claverie et al. Farmaco, Edizione Scientifica 1973, 28(7), 523-7.
Krishnan et al. J. Heterocyclic Chem. 1988, 25(2), 447-52.
Kyriakis et al,; “The stress-activated protein kinase subfamily of c-Jun kinases”; Letter to Nature, vol. 369, pp. 156-160, 1994.
Xia et al.; “Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis”; Science, vol. 270, pp. 1326-1331, 1995.
Pulverer et al.; “Phosphorylation of c-junmediated by MAP kinases”; Letters to Nature, vol. 353, pp. 670-674, 1991.
Gupta et al.; “Selective interaction of JNK protein kinase isoforms with transcription factors”; The Embo Journal, vol. 15, No. 11, pp. 2760-2770, 1996.
Mohlt et al.; “p493F12Kinase: A Novel MAP Kinase Expressed in a Subset of Neurons in the Human Nervous System”; Neuron, vol. 14, pp. 67-78, 1995.
Kuan et al.; “The Jnk1 and Jnk2 Protein Kinases Are Required for Regional Specific Apoptosis during Early Brain Development”; Neuron, vol. 22, pp. 667-676, 1999.
Sabapathy et al.; c-Jun NH2-Terminal Kinase (JNK)1 and JNK2 Have Similar and Stage-dependent Roles in Regulating T Cell Apoptosis and Proliferation; J. Exp. Med., vol, 193, No. 3, pp. 317-328, 2001.
Hirosumi et al.; “A central role for JNK in obesity and insulin resistance”; Nature, vol. 420, pp. 333-336, 2002.
Yang et al.; “Absence of excitotoxicity-Induced apoptosis in the hippocampus of mice lacking the Jnk3 gene”; Letters to Nature, vol. 389, pp. 865-870, 1997.
Ham et al.; “A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death”; Neuron, vol. 14, pp. 927-939, 1995.
Watson et al.; “Phosphorylation of c-Jun Is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons”; The Journal of Neuroscience, vol. 18, pp. 751-762, 1998.
Yuan et al.; “Apoptosis in the nervous system”; Nature, vol. 407, pp. 802-809, 2000.
Xia et al.; “Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease”; PNAS, vol. 98, No. 18, pp. 10433-10438, 2001.
Savage et al.; “Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model is Associated with Amyloid Deposition”; The Journal of Neuroscience, vol. 22, pp. 3376-3385, 2002.
Zhu et al.; “Activation and redistribution of c-Jun N-Terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease”; Journal of Neurochemistry, vol. 76, pp. 435-441, 2001.
Bonni et al.; “Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms”; Science, vol. 286, pp. 1358-1362, 1999.
Han et al.; “BDNF Protects the Neonatal Brain from Hypoxic-Ischemic Injury In Vivo via the ERK Pathway”; The Journal of Neuroscience, vol. 20, pp. 5775-5781, 2000.
Abdel-Aziz El-Taweel et al., Alexandria Journal of Pharmaceutical Sciences, (1998), 12(1), 11-15.
Ghozlan, S.A.S. et al., Egyptian Journal of Pharmaceutical Sciences, (1992), 33(5-6), 859-67.
Marei, Mohamed Gaber, Bulletin of the Chemical Society of Japan, (1993), 66(4), 1172-5.
Rusinov, V.L. et al., Khimiya Geterotsiklicheskikh Soedinenii, (1992), (11), 1560-4.
Marei, Mohamed Gaber, Afinidad, (1993), 50(443), 55-8.
Radinov. R. et al., Journal of Molecular Structure, (1987), 158, 99-108.
Cecchi, L. et al., Farmaco, Edizione Scientifica, (1983), 38(1), 24-8.
Cecchi, L. et al., Farmaco, Edizione Scientifica, (1982), 37(2), 116-22.
Joshi, K. et al., Journal of Heterocyclic Chemistry, (1979), 16(6), 1141-5.
Kocevar, M. et al., Journal of Heterocyclic Chemistry, (1978), 15(7), 1175-84.
Charbonnier et al.,Journal of Molecular Structure, vol. 158, pp. 109-125 (1987).
Huff,Journal of Medicinal Chemistry, vol. 34, No. 8, pp. 2305-2314 (1991).
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL http://ww.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html.

Affiliated with

Also associated with

Rating

Pyrazole compound and medicinal composition containing the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazole compound and medicinal composition containing the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole compound and medicinal composition containing the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3992918